GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC

This study is testing a personalized T-cell therapy called ECT204 in adults with advanced liver cancer (hepatocellular carcinoma, or HCC). The therapy uses a patient's own immune cells, engineered to target a protein called GPC3 found on many liver cancer cells. **You may be eligible if...** - You have confirmed advanced, unresectable, or metastatic hepatocellular carcinoma - Your tumor tests positive for the GPC3 protein - You have already tried at least two different systemic treatments that either did not work or you could not tolerate - Your life expectancy is at least 4 months **You may NOT be eligible if...** - Your tumor does not express the GPC3 protein - You have not yet tried available standard treatments - Your general health is too poor for this type of therapy Talk to your doctor to see if this trial is right for you.